Detail akcie Bioporto online

Business Summary: Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
Financial Summary: BRIEF: For the three months ended 31 March 2025, BioPorto A/S revenues decreased 19% to DKR7.7M. Net loss increased from DKR13.6M to DKR27.5M. Revenues reflect The NGAL test segment decrease of 25% to DKR4.6M, Antibodies segment decrease of 6% to DKR2.5M, Europe segment decrease of 51% to DKR1.4M, Asia segment decrease of 76% to DKR431K. Higher net loss reflects Research and development costs increase from DKR6.3M to DKR17.7M (expense).